Study guide

Immunisation and cancer screening entry points

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Immunisation and cancer screening entry points

Key Takeaways Explain This Topic AI

The adult NIP pneumococcal programme changed to 21-valent vaccine from July 2026.

National lung screening targets eligible high-risk adults aged 50–70.

Bowel-screening participants aged 45–49 can request their first kit.

Last updated: October 2026

Australian National Immunisation Program & Cancer Screening Programs

Preventive medicine and population screening form the backbone of primary healthcare in Australia. Medical practitioners must demonstrate mastery of the Australian National Immunisation Program (NIP) schedule, organized population cancer screening algorithms, and absolute cardiovascular disease risk assessment to optimize health outcomes and prevent premature morbidity and mortality.

The Australian National Immunisation Program (NIP) Schedule

The National Immunisation Program (NIP), funded by the Commonwealth and State/Territory governments, provides free vaccines to eligible Australians across defined life stages. Vaccinations must be registered promptly on the Australian Immunisation Register (AIR).

Clinical Nuances of Childhood Immunisation

Hepatitis B at Birth : Administered within 24 hours of birth to prevent perinatal mother-to-child transmission. If the mother is hepatitis B surface antigen (HBsAg) positive, the neonate must receive both the hepatitis B vaccine and Hepatitis B Immunoglobulin (HBIG) within 12 hours of birth in separate anatomical limbs.

Rotavirus Vaccine Safety : Live-attenuated oral vaccine with strict age boundaries to minimize the rare risk of intussusception. The first dose must be given between 6 weeks and 14 weeks and 6 days of age; the final dose must be completed by 24 weeks and 6 days of age. Never initiate rotavirus vaccination in infants aged 15 weeks or older.

MMR vs MMRV : The combination MMRV (measles-mumps-rubella-varicella) vaccine carries a higher rate of post-vaccination febrile convulsions if given as the first measles-containing dose. Therefore, MMR is given at 12 months, and MMRV is reserved for 18 months.

Adolescent School-Based Immunisation Programs

Year 7 (Aged 12 to 13 years) :

Human Papillomavirus (9vHPV - Gardasil 9) : Administered as a single dose in the national school program for immunocompetent adolescents. Australia transitioned from a two-dose to a single-dose schedule based on robust global evidence demonstrating equivalent long-term protection against high-risk oncogenic HPV types (16, 18, 31, 33, 45, 52, 58) and anogenital wart types (6, 11). Immunocompromised individuals still require a 3-dose schedule.

dTpa Booster : Reduced-antigen diphtheria-tetanus-acellular pertussis booster.

Year 10 (Aged 15 to 16 years) :

Meningococcal ACWY (MenACWY) : Quadrivalent conjugate booster targeting high-carriage adolescent cohorts to induce herd immunity.

Maternal Immunisation in Pregnancy

Maternal vaccination provides dual protection by preventing severe maternal morbidity and conferring passive protection to the neonate via transplacental IgG antibodies before the infant can be immunized:

dTpa (Pertussis-containing vaccine) : Recommended and funded for administration between 20 and 32 weeks of gestation during EVERY pregnancy , regardless of the interval since a previous dose. Receiving the vaccine during this window maximizes maternal antibody production and transplacental transfer.

Influenza Vaccine : Inactivated influenza vaccine is recommended and funded at any stage (trimester) of pregnancy , providing protection during maternal gestation and reducing infant influenza hospitalisation during the first 6 months of life.

Respiratory Syncytial Virus (RSV) Vaccine : Recombinant RSV prefusion F protein vaccine (Abrysvo) administered between 28 and 36 weeks of pregnancy to protect infants from severe lower respiratory tract illness (bronchiolitis and pneumonia).

Adult and risk-based immunisation

From July 2026, adult NIP pneumococcal vaccination uses 21vPCV (Capvaxive), replacing Prevenar 13 and Pneumovax 23 on the adult NIP. It is funded from 65 for non-Indigenous adults, 25 for First Nations adults and 18 for specified risk conditions. After previous pneumococcal vaccination, generally wait at least twelve months. The childhood vaccine and schedule differ.

Shingrix is a two-dose recombinant zoster vaccine, funded from 65 years, from 50 for First Nations adults, and for specified high-risk immunocompromised adults from 18. Influenza is annual for funded groups; use the age-appropriate current-season formulation rather than an obsolete fixed valency. RSV vaccination and infant monoclonal-antibody protection have separate age/risk/funding pathways. Check the current Handbook and state program rather than treating TGA approval as automatic NIP funding.

Review catch-up, occupational exposure, pregnancy and immunocompromise. A severe allergic reaction to a previous dose/component is different from a mild cold or local soreness. Live vaccines have pregnancy/immunocompromise restrictions; inactivated products have different considerations. Document informed consent, batch/site, adverse events and AIR reporting under current requirements.

Check history before a vaccine decision

For an older adult, confirm previous doses, age, risk conditions and the current vaccine product rather than repeating an old schedule automatically. A TGA-approved product is not necessarily funded for every age group. Explain expected reactions and serious warning signs, document consent, product, batch and administration, and use the adverse-event reporting pathway when indicated. A missed childhood dose usually leads to catch-up planning rather than restarting every series.

Australia's Four Organised Population Cancer Screening Programs

Australia maintains four nationwide, evidence-based, government-funded population cancer screening programs designed to detect malignancies at early, curable stages.

Primary references (checked 7 October 2026): Current Immunisation Handbook ; 2026 adult pneumococcal update ; National lung screening .